The antiangiogenic effects of integrin α5β1 inhibitor (ATN-161) in vitro and in vivo

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 10, 2011, Pages 7213-7220

  Wang, Wenqiu ^a   Wang, Fenghua ^a   Lu, Fengqing ^a   Xu, Shan ^a   Hu, Weiting ^a   Huang, Jiannan ^a   Gu, Qing ^a   Sun, Xiaodong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AF 564; BEVACIZUMAB; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VERY LATE ACTIVATION ANTIGEN 5; ACETYL PROLYL HISTIDYL SERYL CYSTEINYL ASPARAGINAMIDE; ACETYL-PROLYL-HISTIDYL-SERYL-CYSTEINYL-ASPARAGINAMIDE; ANGIOGENESIS INHIBITOR; OLIGOPEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANGIOGRAPHY; HISTOLOGY; HUMAN; HUMAN CELL; LASER COAGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; WESTERN BLOTTING; ANIMAL; BROWN NORWAY RAT; CAPILLARY; CELL CULTURE; CELL MOTION; CHOROID; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CAPILLARIES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTEGRIN ALPHA5BETA1; LASER COAGULATION; OLIGOPEPTIDES; RATS; RATS, INBRED BN; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80655147260     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-7097     Document Type: Article

References (48)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901.
2. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ. 2003;326:485-488.
3. Foster RA. Age-related macular degeneration: a leading cause of blindness. Med J Aust. 1997;166:331.
4. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans. 2003;31:1171-1177.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
6. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113: 633, e631-634.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
8. Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18:1573-1580.
9. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
10. Takeda A, Baffi JZ, Kleinman ME, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460:225-230.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
12. Khalili P, Arakelian A, Chen G, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006;5:2271-2280.
13. Donate F, Parry GC, Shaked Y, et al. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res. 2008;14:2137-2144.
14. Zeng ZZ, Yao H, Staszewski ED, et al. alpha(5)beta(1) Integrin ligand PHSRN induces invasion and alpha(5) mRNA in endothelial cells to stimulate angiogenesis. Transl Oncol. 2009;2:8-20.
15. Alge-Priglinger CS, Kreutzer T, Obholzer K, et al. Oxidative stressmediated induction of MMP-1 and MMP-3 in human RPE cells. Invest Ophthalmol Vis Sci. 2009;50:5495-5503.
16. Zhu J, Wang YS, Zhang J, et al. Focal adhesion kinase signaling pathway participates in the formation of choroidal neovascularization and regulates the proliferation and migration of choroidal microvascular endothelial cells by acting through HIF-1 and VEGF expression in RPE cells. Exp Eye Res. 2009;88:910-918.
17. Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. J Cell Sci. 1999;112:569-578.
18. Umeda N, Kachi S, Akiyama H, et al. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol. 2006;69:1820-1828.
19. Bhaskar V, Fox M, Breinberg D, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008;26:7-12.
20. Maier AK, Kociok N, Zahn G, et al. Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule. Curr Eye Res. 2007;32:801-812.
21. Muether PS, Dell S, Kociok N, et al. The role of integrin alpha5beta1 in the regulation of corneal neovascularization. Exp Eye Res. 2007;85:356-365.
22. Zahn G, Vossmeyer D, Stragies R, et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol. 2009;127:1329-1335.
23. Heckmann D, Meyer A, Laufer B, Zahn G, Stragies R, Kessler H. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. Chembiochem. 2008;9:1397-1407.
24. Mould AP, Koper EJ, Byron A, Zahn G, Humphries MJ. Mapping the ligand-binding pocket of integrin alpha5beta1 using a gain-of-function approach. Biochem J. 2009;424:179-189.
25. Livant DL, Brabec RK, Kurachi K, et al. The PHSRN sequence induces extracellular matrix invasion and accelerates wound healing in obese diabetic mice. J Clin Invest. 2000;105:1537-1545.
26. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cellbinding domain of fibronectin. Am J Pathol. 2000;156:1345-1362.
27. Livant DL, Brabec RK, Pienta KJ, et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 2000;60:309-320.
28. Yao H, Veine DM, Zeng ZZ, Fay KS, Staszewski ED, Livant DL. Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation. Clin Exp Metastasis. 2010;27:173-184.
29. Huber G, Beck SC, Grimm C, et al. Spectral domain optical coherence tomography in mouse models of retinal degeneration. Invest Ophthalmol Vis Sci. 2009;50:5888-5895.
30. Parravano M, Oddone F, Boccassini B, et al. Reproducibility of macular thickness measurements using Cirrus SD-OCT in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51:4788-4791.
31. Chung EJ, Lew YJ, Lee H, Koh HJ. OCT-guided hyaloid release for vitreomacular traction syndrome. Korean J Ophthalmol. 2008;22:169-173.
32. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:1635-1641.
33. Wang FH, Sun XD, Zhang X, et al. Role of pigment epitheliumderived factor on proliferation and migration of choroidal capillary endothelium induced by vascular endothelial growth factor in vitro. Chin Med J (Engl). 2007;120:1534-1538.
34. Soares R, Guo S, Gartner F, Schmitt FC, Russo J. 17 beta-Estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk. Angiogenesis. 2003;6:271-281.
35. Gamble JR, Matthias LJ, Meyer G, et al. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol. 1993;121:931-943.
36. Parsons-Wingerter P, Kasman IM, Norberg S, et al. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol. 2005;167:193-211.
37. Klein S, de Fougerolles AR, Blaikie P, et al. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol. 2002;22:5912-5922.
38. Enaida H, Ito T, Oshima Y, et al. Effect of growth factors on expression of integrin subtypes in microvascular endothelial cells isolated from bovine retinas. Fukushima J Med Sci. 1998;44:43-52.
39. Li R, Maminishkis A, Zahn G, Vossmeyer D, Miller SS. Integrin alpha5beta1 mediates attachment, migration, and proliferation in human retinal pigment epithelium: relevance for proliferative retinal disease. Invest Ophthalmol Vis Sci. 2009;50:5988-5996.
40. Zahn G, Volk K, Lewis GP, et al. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci. 2010;51:1028-1035.
41. Wilson SH, Ljubimov AV, Morla AO, et al. Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase. Invest Ophthalmol Vis Sci. 2003;44:1704-1715.
42. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285: 1028-1032.
43. Gingras D, Lamy S, Beliveau R. Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem J. 2000;348:273-280.
44. Del Pozo MA, Kiosses WB, Alderson NB, Meller N, Hahn KM, Schwartz MA. Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI. Nat Cell Biol. 2002;4:232-239.
45. Lee MY, Huang JP, Chen YY, et al. Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1. PLoS One. 2009;4:e6913.
46. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A. 1997;94:13612-13617.
47. Wijelath ES, Rahman S, Namekata M, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res. 2006;99:853-860.
48. Srinivasan VJ, Ko TH, Wojtkowski M, et al. Noninvasive volumetric imaging and morphometry of the rodent retina with high-speed, ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci. 2006;47:5522-5528.